An inactive metabolite of PROGESTERONE by reduction at C5, C3, and C20 position. Pregnanediol has two hydroxyl groups, at 3-alpha and 20-alpha. It is detectable in URINE after OVULATION and is found in great quantities in the pregnancy urine.
Method to determine the occurrence of OVULATION by direct or indirect means. Indirect methods examine the effects of PROGESTERONE on cervical mucus (CERVIX MUCUS), or basal body temperature. Direct ovulation detection, generally used in fertility treatment, involves analyses of circulating hormones in blood and ULTRASONOGRAPHY.
An aromatized C18 steroid with a 3-hydroxyl group and a 17-ketone, a major mammalian estrogen. It is converted from ANDROSTENEDIONE directly, or from TESTOSTERONE via ESTRADIOL. In humans, it is produced primarily by the cyclic ovaries, PLACENTA, and the ADIPOSE TISSUE of men and postmenopausal women.
A metabolite of 17-ALPHA-HYDROXYPROGESTERONE, normally produced in small quantities by the GONADS and the ADRENAL GLANDS, found in URINE. An elevated urinary pregnanetriol is associated with CONGENITAL ADRENAL HYPERPLASIA with a deficiency of STEROID 21-HYDROXYLASE.
A hydroxylated metabolite of ESTRADIOL or ESTRONE that has a hydroxyl group at C3, 16-alpha, and 17-beta position. Estriol is a major urinary estrogen. During PREGNANCY, a large amount of estriol is produced by the PLACENTA. Isomers with inversion of the hydroxyl group or groups are called epiestriol.
The period from onset of one menstrual bleeding (MENSTRUATION) to the next in an ovulating woman or female primate. The menstrual cycle is regulated by endocrine interactions of the HYPOTHALAMUS; the PITUITARY GLAND; the ovaries; and the genital tract. The menstrual cycle is divided by OVULATION into two phases. Based on the endocrine status of the OVARY, there is a FOLLICULAR PHASE and a LUTEAL PHASE. Based on the response in the ENDOMETRIUM, the menstrual cycle is divided into a proliferative and a secretory phase.
The reproductive organ (GONADS) in female animals. In vertebrates, the ovary contains two functional parts: the OVARIAN FOLLICLE for the production of female germ cells (OOGENESIS); and the endocrine cells (GRANULOSA CELLS; THECA CELLS; and LUTEAL CELLS) for the production of ESTROGENS and PROGESTERONE.
The discharge of an OVUM from a rupturing follicle in the OVARY.
Men and women working in the provision of health services, whether as individual practitioners or employees of health institutions and programs, whether or not professionally trained, and whether or not subject to public regulation. (From A Discursive Dictionary of Health Care, 1976)
An agency of the PUBLIC HEALTH SERVICE concerned with the overall planning, promoting, and administering of programs pertaining to maintaining standards of quality of foods, drugs, therapeutic devices, etc.
The study of the origin, nature, properties, and actions of drugs and their effects on living organisms.
Disorders that result from the intended use of PHARMACEUTICAL PREPARATIONS. Included in this heading are a broad variety of chemically-induced adverse conditions due to toxicity, DRUG INTERACTIONS, and metabolic effects of pharmaceuticals.
The branch of pharmacology that deals directly with the effectiveness and safety of drugs in humans.
Attitudes of personnel toward their patients, other professionals, toward the medical care system, etc.
Systems developed for collecting reports from government agencies, manufacturers, hospitals, physicians, and other sources on adverse drug reactions.

Caffeine consumption and menstrual function. (1/115)

The relation between caffeine intake and menstrual function was examined in 403 healthy premenopausal women who belonged to Kaiser Permanente Medical Care Program in 1990-1991. A telephone interview collected information about caffeinated beverage intake as well as other lifestyle, demographic, occupational, and environmental factors. Subjects collected daily urine samples and completed a daily diary for an average of five menstrual cycles. Metabolites of estrogen and progesterone were measured in the urine, each cycle was characterized as anovulatory or ovulatory, and a probable day of ovulation was selected when appropriate. Logistic regression and repeated measures analyses were performed on menstrual parameters. Women whose caffeine consumption was heavy (>300 mg of caffeine per day) had less than a third of the risk for long menses (> or =8 days) compared with women who did not consume caffeine (adjusted odds ratio = 0.30, 95% confidence interval 0.14-0.66). Those whose caffeine consumption was heavy also had a doubled risk for short cycle length (< or =24 days) (adjusted odds ratio = 2.00, 95% confidence interval 0.98-4.06); this association was also evident in those whose caffeine consumption was heavy who did not smoke (adjusted odds ratio = 2.11, 95% confidence interval 1.03-4.33). Caffeine intake was not strongly related to an increased risk for anovulation, short luteal phase (< or =10 days), long follicular phase (> or =24 days), long cycle (> or =36 days), or measures of within-woman cycle variability.  (+info)

Reproducibility and validity of radioimmunoassays for urinary hormones and metabolites in pre- and postmenopausal women. (2/115)

The reproducibility of RIAs of circulating sex hormones has been evaluated as part of recent epidemiological investigations, but none seem to have addressed the reproducibility or validity of RIAs for urinary hormones or their metabolites. As part of a case-control study of breast cancer in Asian-American women, 12-h overnight urine samples were obtained, and a methodological study was conducted to identify laboratories capable of assaying urinary hormones. For the reproducibility component of this study, two laboratories with extensive experience in hormone assays measured urinary estrone, estradiol, estriol, pregnanediol glucuronide, and estrone glucuronide using samples from 15 women (5 midfollicular, 5 midluteal, and 5 postmenopausal). Variance estimates from these measurements were used to calculate the laboratory variability (coefficient of variation) and to assess the magnitude of the biological variability among the women in relation to the total variability (intraclass correlation coefficient). For the validity component, urinary estrone, estradiol, and estriol levels were measured in the same samples by gas chromatography-mass spectroscopy in the laboratory of Dr. Herman Adlercreutz (University of Helsinki, Helsinki, Finland). We found that the degree of assay reproducibility differed between the laboratories, but that laboratory variability was usually low compared with the range of hormone values among women, particularly for the estrogens. Values for estrone and estradiol were well correlated among all of the laboratories. For estriol, the RIAs tended to overestimate levels compared with gas chromatography-mass spectroscopy. In one laboratory, assays for pregnanediol glucuronide and estrone glucuronide were consistently reproduced; in the other, the reproducibility of the RIA for pregnanediol glucuronide was problematic, and estrone glucuronide was not measured. Despite some limitations, urinary hormones and their metabolites can be reliably measured by current RIAs in large investigations attempting to link hormone level to disease risk and may be particularly advantageous for studies of postmenopausal women, where serum concentrations of estrone and estradiol are low and assay measurements are not as dependable.  (+info)

Mechanism for the development of ovarian cysts in patients with congenital lipoid adrenal hyperplasia. (3/115)

OBJECTIVE: Although ovarian cysts commonly occur in patients with congenital lipoid adrenal hyperplasia (CLAH), the mechanism of development remains to be determined. To clarify the pathogenesis of the ovarian cysts, endocrinological examinations were performed in patients with CLAH. METHODS: The subjects were three Japanese CLAH patients. Basal body temperature, serum and urinary gonadotropin levels, serum and/or urinary ovarian hormones and mutations of the steroidogenic acute regulatory protein (StAR) gene were examined. RESULTS: The basal body temperature was not biphasic in any patient. Basal LH levels were high in all CLAH patients and markedly responded to LH-releasing hormone in two patients. Urinary gonadotropin analysis revealed repetitive LH surges in the menstrual cycles of the CLAH patients. No increase in the urinary pregnanediol suggested anovulation in all patients, and bilateral ovarian cysts were found in two of the subjects. Examination of the StAR gene revealed a frameshift mutation 840delA at codon 238, a nonsense mutation Q258X at codon 258, a homozygotic mutation at Q258X, and a compound heterozygotic mutation with 251insG and Q258X. CONCLUSIONS: We concluded that the development of ovarian cysts may be derived from continued anovulation in CLAH patients. Elevated LH levels may be explained by increased sensitivity of the anterior pituitary to circulating estrogen.  (+info)

Side of ovulation and cycle characteristics in normally fertile women. (4/115)

This study was undertaken to establish whether ovulation in humans alternates consistently from right to left ovary in successive cycles and whether the site of ovulation affects the next cycle length or the hormonal profiles. A total of 199 cycles in 80 normally fertile women were studied. The volunteers were monitored with ultrasonography to determine the day and side of ovulation and to calculate follicular and luteal phase lengths. Urinary hormone concentrations were also assayed. Right-sided ovulations occurred in 104 of the 199 cycles (52.3%; not significantly different from 50%). Alternate ovulations occurred in 61 of the 119 pairs of succeeding cycles (51.3%, not significant). The follicular phase length in contralateral ovulation (14.59 +/- 0.33 days; mean +/- SEM) did not differ significantly from that of ipsilateral ovulation (14.59 +/- 0. 37 days). There were also no significant differences in urinary concentrations of oestrone-3-glucuronide, pregnanediol-3alpha glucuronide, follicle stimulating hormone, and luteinizing hormone between ipsilateral and contralateral ovulation in either early follicular, peri-ovulatory or luteal phase of the cycle. It is concluded that in normally fertile women, the cycle length and the hormonal profile are independent of the, most probably random, site of ovulation.  (+info)

Use of clomiphene and luteinizing hormone/follicle stimulating hormone-releasing hormone in investigation of ovulatory failure. (5/115)

A luteinizing hormone/follicle-stimulating hormone-releasing hormone (LH/FSH-RH) test was performed in 70 women with amenorrhoea or anovulatory infertility, or both, and a clomiphene stimulation test was also performed in 24 of these patients. Most patients responded to LH/FSH-RH with significant increases in LH and FSH. In women with gonadal dysgenesis or premature ovarian failure exaggerated responses were observed after LH/FSH-RH and there was no change in high basal LH levels after clomiphene. Patients with absent or impaired responses to LH/FSH-RH failed to respond to clomiphene. All patients with anovulatory menstrual cycles responded to both LH/FSH-RH and clomiphene, while seven out of 13 amenorrhoeic patients with a normal LH/FSH-RH response showed an early LH rise during clomiphene treatment and six were unresponsive. These results suggest a difference between the two groups at hypothalamic level with consequent therapeutic implications.  (+info)

Performance characteristics of a carbon isotope ratio method for detecting doping with testosterone based on urine diols: controls and athletes with elevated testosterone/epitestosterone ratios. (6/115)

BACKGROUND: Carbon isotope ratio methods are used in doping control to determine whether urinary steroids are endogenous or pharmaceutical. METHODS: Gas chromatography-combustion-isotope ratio mass spectrometry (GC-C-IRMS) was used to determine the delta(13)C values for 5 beta-androstane-3 alpha,17 beta-diyl diacetate (5 beta A), 5 alpha-androstane-3 alpha,17 beta-diyl diacetate (5 alpha A), and 5 beta-pregnane-3 alpha,20 alpha-diyl diacetate (5 beta P) in a control group of 73 healthy males and 6 athletes with testosterone/epitestosterone ratios (T/E) >6. RESULTS: The within-assay precision SDs for 5 beta A, 5 alpha A, and 5 beta P were +/- 0.27 per thousand, +/- 0.38 per thousand, and +/- 0.28 per thousand, respectively. The between-assay precision SDs ranged from +/- 0.40 per thousand to +/- 0.52 per thousand. The system suitability and batch acceptance scheme is based on SDs. For the control group, the mean delta(13)C (SD) values were -25.69 per thousand (+/- 0.92 per thousand), -26.35 per thousand (+/- 0.68 per thousand), and -24.26 per thousand (+/- 0.70 per thousand), for 5 beta A, 5 alpha A, and 5 beta P, respectively. 5 beta P was greater than 5 beta A and 5 alpha A (P <0.01), and 5 beta A was greater than 5 alpha A (P <0.01). The means - 3 SD were -28.46 per thousand, -28.39 per thousand, and -26.37 per thousand for 5 beta A, 5 alpha A, and 5 beta P, respectively. The maximum difference between 5 beta P and 5 beta A was 3.2 per thousand, and the maximum 5 beta A/5 beta P was 1.13. Three athletes with chronically elevated T/Es had delta(13)C values consistent with testosterone administration and three did not. CONCLUSIONS: This GC-C-IRMS assay of urine diols has low within- and between-assay SDs; therefore, analysis of one urine sample suffices for doping control. The means, SDs, +/-3 SDs, and ranges of delta(13)C values in a control group are established. In comparison, testosterone users have low 5 beta A and 5 alpha A, large differences between 5 beta A or 5 alpha A and 5 beta P, and high 5 beta A/5 beta P and 5 alpha A/5 beta P ratios.  (+info)

Cyclic changes in the circulating and urinary levels of ovarian steroids in the adult female owl monkey (Aotus trivirgatus). (7/115)

Circulating levels of oestrone and progesterone were measured by radioimmunoassays in plasma samles from 5 female owl monkeys on 60 consecutive days. Both steroids exhibited cyclic fluctuations and based on nadir to nadir intervals the ovarian cycle was estimated to be 15.92 +/- 0.26 days. Levels of oestrone and pregnanediol-3 alpha-glucuronide were also measured in daily urine samples. The fluctuations of urinary steroids reflected those observed in plasma. Ketamine sedation had no effect on the length of the cycle. Peak values of plasma progesterone and oestrone were 250.48 +/- 11.37 and 3.59 +/- 0.066 ng/ml respectively. There was no clear hormonal distinction between the follicular and luteal phase of the cycle in these owl monkeys.  (+info)

Urinary hormone levels during the natural menstrual cycle: the effect of age. (8/115)

A number of studies have identified hormonal changes in women during their reproductive lifespan, many focusing upon changes in women over the age of 40 years. The present study has determined the effect of increasing age on hormone levels over three decades. Daily early morning urine samples were assayed for estrone-3-glucuronide (E3 G), pregnanediol-3-glucuronide (P3 G), testosterone-17-glucuronide (T17 G), FSH and LH. An examination of the validity of using creatinine as a volume adjuster in urine samples formed an integral part of the analysis. Volunteers were healthy women who had regular (25-35 days) cycles, were not taking oral contraceptives, hormone therapies or any other medication. Three age groups were compared: 20-29 years (n=13), 30-39 years (n=9) and 40-49 years (n=13). Statistical analyses were carried out using two-way ANOVA and post hoc t-tests. Creatinine excretion, despite revealing no cycle-related variation in any age group, showed a decline with increasing age. Creatinine output was significantly lower in the 40-49 years age group in all phases of the cycle than in the 20-29 and 30-39 groups (P<0.0001). Uncorrected levels of E3 G were significantly higher in the 30-39 years group when compared with the 40-49 age group (P<0.0001). Uncorrected P3 G output was significantly higher in women aged 20-29 years than in women aged 40-49 years (P<0.001) and levels of uncorrected T17 G were higher in the 20-29 year age group when compared with the 30-39 or 40-49 years age group (P<0.0001). The present study is consistent with previous reports that have revealed a decline in creatinine clearance with increasing age, and therefore casts into some doubt the validity of using creatinine clearance as a procedure to correct for volume fluctuations in differing age groups of women. The study also demonstrates unequivocally that age-related variations in hormone levels are not restricted to women over 40 years of age. The novel finding of highly significant differences in mean levels of T17 G between the age groups is of considerable interest. It is presently unclear whether this resulted from specifically increased ovarian and/or adrenal secretion. The possible impacts of changes in testosterone levels during the female reproductive lifespan merits further study.  (+info)

Pregnanediol is a steroid hormone that is produced as a metabolite of progesterone. It is primarily used as a biomarker to measure the exposure to progesterone, particularly in cases where progesterone levels need to be monitored, such as during pregnancy or in certain medical conditions. Pregnanediol can be measured in urine, blood, or other bodily fluids and is often used in clinical and research settings to assess hormonal status. It is important to note that pregnanediol itself does not have any known physiological effects on the body, but rather serves as an indicator of progesterone levels.

Ovulation detection refers to the process of identifying the time period during which an ovary releases an oocyte (mature egg) from its follicle, ready for fertilization. This is a crucial aspect of reproductive health and assisted reproduction technologies (ART), such as in vitro fertilization (IVF).

There are several methods to detect ovulation, including:

1. Ovulation Predictor Kits (OPKs): These are home-use test kits that detect the surge of luteinizing hormone (LH) in urine, which occurs 24-36 hours prior to ovulation.
2. Basal Body Temperature (BBT) Charting: This involves tracking and recording daily basal body temperature (the lowest temperature attained by the body during rest), as it tends to rise slightly after ovulation due to increased progesterone levels.
3. Hormonal Monitoring: Blood tests can be used to measure hormone levels, such as estrogen and progesterone, throughout a menstrual cycle to detect ovulation.
4. Transvaginal Ultrasound: This imaging technique is often used in clinical settings to monitor follicular development and determine the exact time of ovulation by observing changes in the ovarian follicle and endometrial lining.
5. Saliva Ferning Tests: A microscope is used to examine the patterns formed by dried saliva, which can indicate increased estrogen levels prior to ovulation.

Accurate ovulation detection helps individuals or couples trying to conceive optimize their chances of success and provides valuable information for healthcare providers in managing reproductive health issues.

Estrone is a type of estrogen, which is a female sex hormone. It's one of the three major naturally occurring estrogens in women, along with estradiol and estriol. Estrone is weaker than estradiol but has a longer half-life, meaning it remains active in the body for a longer period of time.

Estrone is produced primarily in the ovaries, adrenal glands, and fat tissue. In postmenopausal women, when the ovaries stop producing estradiol, estrone becomes the dominant form of estrogen. It plays a role in maintaining bone density, regulating the menstrual cycle, and supporting the development and maintenance of female sexual characteristics.

Like other forms of estrogen, estrone can also have effects on various tissues throughout the body, including the brain, heart, and breast tissue. Abnormal levels of estrone, either too high or too low, can contribute to a variety of health issues, such as osteoporosis, menstrual irregularities, and increased risk of certain types of cancer.

Pregnanetriol is not a medication, but rather a metabolite of the hormone progesterone. It is a steroid compound that is produced in the body and can be detected in urine. Pregnanetriol is often used as a biomarker to help diagnose certain medical conditions related to steroid hormone metabolism, such as congenital adrenal hyperplasia (CAH). In these cases, abnormal levels of pregnanetriol in the urine can indicate an enzyme deficiency that affects the production or breakdown of steroid hormones.

Estriol is a type of estrogen, which is a female sex hormone. It is produced in the placenta during pregnancy and is used as a marker for fetal growth and development. Estriol levels can be measured in the mother's urine or blood to assess fetal well-being during pregnancy. Additionally, synthetic forms of estriol are sometimes used in hormone replacement therapy to treat symptoms of menopause.

The menstrual cycle is a series of natural changes that occur in the female reproductive system over an approximate 28-day interval, marking the body's preparation for potential pregnancy. It involves the interplay of hormones that regulate the growth and disintegration of the uterine lining (endometrium) and the release of an egg (ovulation) from the ovaries.

The menstrual cycle can be divided into three main phases:

1. Menstrual phase: The cycle begins with the onset of menstruation, where the thickened uterine lining is shed through the vagina, lasting typically for 3-7 days. This shedding occurs due to a decrease in estrogen and progesterone levels, which are hormones essential for maintaining the endometrium during the previous cycle.

2. Follicular phase: After menstruation, the follicular phase commences with the pituitary gland releasing follicle-stimulating hormone (FSH). FSH stimulates the growth of several ovarian follicles, each containing an immature egg. One dominant follicle usually becomes selected to mature and release an egg during ovulation. Estrogen levels rise as the dominant follicle grows, causing the endometrium to thicken in preparation for a potential pregnancy.

3. Luteal phase: Following ovulation, the ruptured follicle transforms into the corpus luteum, which produces progesterone and estrogen to further support the endometrial thickening. If fertilization does not occur within approximately 24 hours after ovulation, the corpus luteum will degenerate, leading to a decline in hormone levels. This drop triggers the onset of menstruation, initiating a new menstrual cycle.

Understanding the menstrual cycle is crucial for monitoring reproductive health and planning or preventing pregnancies. Variations in cycle length and symptoms are common among women, but persistent irregularities may indicate underlying medical conditions requiring further evaluation by a healthcare professional.

An ovary is a part of the female reproductive system in which ova or eggs are produced through the process of oogenesis. They are a pair of solid, almond-shaped structures located one on each side of the uterus within the pelvic cavity. Each ovary measures about 3 to 5 centimeters in length and weighs around 14 grams.

The ovaries have two main functions: endocrine (hormonal) function and reproductive function. They produce and release eggs (ovulation) responsible for potential fertilization and development of an embryo/fetus during pregnancy. Additionally, they are essential in the production of female sex hormones, primarily estrogen and progesterone, which regulate menstrual cycles, sexual development, and reproduction.

During each menstrual cycle, a mature egg is released from one of the ovaries into the fallopian tube, where it may be fertilized by sperm. If not fertilized, the egg, along with the uterine lining, will be shed, leading to menstruation.

Ovulation is the medical term for the release of a mature egg from an ovary during a woman's menstrual cycle. The released egg travels through the fallopian tube where it may be fertilized by sperm if sexual intercourse has occurred recently. If the egg is not fertilized, it will break down and leave the body along with the uterine lining during menstruation. Ovulation typically occurs around day 14 of a 28-day menstrual cycle, but the timing can vary widely from woman to woman and even from cycle to cycle in the same woman.

During ovulation, there are several physical changes that may occur in a woman's body, such as an increase in basal body temperature, changes in cervical mucus, and mild cramping or discomfort on one side of the lower abdomen (known as mittelschmerz). These symptoms can be used to help predict ovulation and improve the chances of conception.

It's worth noting that some medical conditions, such as polycystic ovary syndrome (PCOS) or premature ovarian failure, may affect ovulation and make it difficult for a woman to become pregnant. In these cases, medical intervention may be necessary to help promote ovulation and increase the chances of conception.

"Health personnel" is a broad term that refers to individuals who are involved in maintaining, promoting, and restoring the health of populations or individuals. This can include a wide range of professionals such as:

1. Healthcare providers: These are medical doctors, nurses, midwives, dentists, pharmacists, allied health professionals (like physical therapists, occupational therapists, speech therapists, dietitians, etc.), and other healthcare workers who provide direct patient care.

2. Public health professionals: These are individuals who work in public health agencies, non-governmental organizations, or academia to promote health, prevent diseases, and protect populations from health hazards. They include epidemiologists, biostatisticians, health educators, environmental health specialists, and health services researchers.

3. Health managers and administrators: These are professionals who oversee the operations, finances, and strategic planning of healthcare organizations, such as hospitals, clinics, or public health departments. They may include hospital CEOs, medical directors, practice managers, and healthcare consultants.

4. Health support staff: This group includes various personnel who provide essential services to healthcare organizations, such as medical records technicians, billing specialists, receptionists, and maintenance workers.

5. Health researchers and academics: These are professionals involved in conducting research, teaching, and disseminating knowledge related to health sciences, medicine, public health, or healthcare management in universities, research institutions, or think tanks.

The World Health Organization (WHO) defines "health worker" as "a person who contributes to the promotion, protection, or improvement of health through prevention, treatment, rehabilitation, palliation, health promotion, and health education." This definition encompasses a wide range of professionals working in various capacities to improve health outcomes.

The United States Food and Drug Administration (FDA) is a federal government agency responsible for protecting public health by ensuring the safety, efficacy, and security of human and veterinary drugs, biological products, medical devices, our country's food supply, cosmetics, and products that emit radiation. The FDA also provides guidance on the proper use of these products, and enforces laws and regulations related to them. It is part of the Department of Health and Human Services (HHS).

Pharmacology is the branch of medicine and biology concerned with the study of drugs, their actions, and their uses. It involves understanding how drugs interact with biological systems to produce desired effects, as well as any adverse or unwanted effects. This includes studying the absorption, distribution, metabolism, and excretion of drugs (often referred to as ADME), the receptors and biochemical pathways that drugs affect, and the therapeutic benefits and risks of drug use. Pharmacologists may also be involved in the development and testing of new medications.

Drug-related side effects and adverse reactions refer to any unintended or harmful outcome that occurs during the use of a medication. These reactions can be mild or severe and may include predictable, known responses (side effects) as well as unexpected, idiosyncratic reactions (adverse effects). Side effects are typically related to the pharmacologic properties of the drug and occur at therapeutic doses, while adverse reactions may result from allergic or hypersensitivity reactions, overdoses, or interactions with other medications or substances.

Side effects are often dose-dependent and can be managed by adjusting the dose, frequency, or route of administration. Adverse reactions, on the other hand, may require discontinuation of the medication or treatment with antidotes or supportive care. It is important for healthcare providers to monitor patients closely for any signs of drug-related side effects and adverse reactions and to take appropriate action when necessary.

Clinical pharmacology is a branch of medicine that deals with the study of drugs and their interactions with living organisms. It involves understanding how drugs are absorbed, distributed, metabolized, and excreted by the body, as well as their therapeutic effects, side effects, and toxicity. Clinical pharmacology also encompasses the design and conduct of clinical trials to evaluate the safety and efficacy of new drugs in human subjects. The ultimate goal of clinical pharmacology is to optimize drug therapy for individual patients by considering factors such as age, sex, genetics, lifestyle, and comorbidities. In summary, clinical pharmacology is the application of pharmacological principles to the practice of medicine for the benefit of patients.

The "attitude of health personnel" refers to the overall disposition, behavior, and approach that healthcare professionals exhibit towards their patients or clients. This encompasses various aspects such as:

1. Interpersonal skills: The ability to communicate effectively, listen actively, and build rapport with patients.
2. Professionalism: Adherence to ethical principles, confidentiality, and maintaining a non-judgmental attitude.
3. Compassion and empathy: Showing genuine concern for the patient's well-being and understanding their feelings and experiences.
4. Cultural sensitivity: Respecting and acknowledging the cultural backgrounds, beliefs, and values of patients.
5. Competence: Demonstrating knowledge, skills, and expertise in providing healthcare services.
6. Collaboration: Working together with other healthcare professionals to ensure comprehensive care for the patient.
7. Patient-centeredness: Focusing on the individual needs, preferences, and goals of the patient in the decision-making process.
8. Commitment to continuous learning and improvement: Staying updated with the latest developments in the field and seeking opportunities to enhance one's skills and knowledge.

A positive attitude of health personnel contributes significantly to patient satisfaction, adherence to treatment plans, and overall healthcare outcomes.

Adverse Drug Reaction (ADR) Reporting Systems are spontaneous reporting systems used for monitoring the safety of authorized medicines in clinical practice. These systems collect and manage reports of suspected adverse drug reactions from healthcare professionals, patients, and pharmaceutical companies. The primary objective of ADR reporting systems is to identify new risks or previously unrecognized risks associated with the use of a medication, monitor the frequency and severity of known adverse effects, and contribute to post-marketing surveillance and pharmacovigilance activities.

Healthcare professionals, including physicians, pharmacists, and nurses, are encouraged to voluntarily report any suspected adverse drug reactions they encounter during their practice. In some countries, patients can also directly report any suspected adverse reactions they experience after taking a medication. Pharmaceutical companies are obligated to submit reports of adverse events identified through their own pharmacovigilance activities or from post-marketing surveillance studies.

The data collected through ADR reporting systems are analyzed to identify signals, which are defined as new, changing, or unknown safety concerns related to a medicine or vaccine. Signals are further investigated and evaluated for causality and clinical significance. If a signal is confirmed, regulatory actions may be taken, such as updating the product label, issuing safety communications, or restricting the use of the medication.

Examples of ADR reporting systems include the US Food and Drug Administration's (FDA) Adverse Event Reporting System (FAERS), the European Medicines Agency's (EMA) EudraVigilance, and the World Health Organization's (WHO) Uppsala Monitoring Centre.

Their study extracted pregnanediol from pregnancy urine and revealed that pregnanediol concentration in urine indicates the ... In 1936, Venning and Browne demonstrated the presence of pregnanediol, specifically the glucuronide of pregnanediol in ... estimations of pregnanediol reveal the functionality of a corpus luteum. However, pregnanediol concentrations vary with ... Pregnanediol, or 5β-pregnane-3α,20α-diol, is an inactive metabolic product of progesterone. A test can be done to measure the ...
You are viewing an interactive 3D depiction of the molecule pregnanediol (van) (C21H36O2) from the PQR. ...
Competitive inhibition ELISA assay kit for quantitative detection of Pregnanediol-3-Glucuronide PDG in samples from urine, ... Pregnanediol-3-Glucuronide (PDG) ELISA Kit - 96-wells plate. https://www.gen.bg/shop/0321-k037-h1-pregnanediol-3-glucuronide- ...
Competitive inhibition ELISA assay kit for quantitative detection of Pregnanediol-3-Glucuronide PDG in samples from urine, ... Pregnanediol-3-Glucuronide (PDG) ELISA Kit - 5x 96-wells plate. https://www.gentaur.be/shop/0321-k037-h5-pregnanediol-3- ...
... including 5b-pregnanediol and 5a-pregnanediol. 5b-pregnanediol is… ... Metabolites of progesterone are measured in urine, including 5b-pregnanediol and 5a-pregnanediol. 5b-pregnanediol is inactive ... PDL exists as two isomers, 5a-pregnanediol and 5b-pregnanediol. 5b-pregnanediol represents the majority end point of endogenous ... 5a-Pregnanediol (male), 5a-Pregnanediol (Post-menopausal), 5a-Pregnanediol (Pre-menopausal), 5a-Tetrahydrocorticosterone, 5a- ...
Pregnanediol determination.. *Thyroid function: increase in PBI, and butanol extractable protein bound iodine and decrease in ...
e. Decreased pregnanediol excretion.. f. Reduced response to metyrapone test.. g. Reduced serum folate concentration. ...
Decreased pregnanediol excretion.. * Reduced response to metyrapone test.. * Reduced serum folate concentration. ...
... were used to measure urine levels of the estrogen metabolite estrone-3-glucuronide and the progesterone metabolite pregnanediol ...
They look at the levels of progesterone metabolite (pregnanediol glucuronide, or PdG) in your urine. ...
Mira provides that clarity with a new kit to monitor levels of pregnanediol glucuronide (PdG) in the urine by measuring ...
The coordinated fluctuation of urinary estrone conjugates and pregnanediol observed in intact animals was disrupted after ... Urine samples were collected noninvasively, and excretion of estrone conjugates and pregnanediol-3-glucuronide (metabolites of ... concentrations to the enzyme immunoassay measurements of urinary estrone conjugates and immunoreactive pregnanediol-3- ...
Figure 8: Example of a good accuracy test while analyzing hormone levels of pregnanediol glucuronide (Pdg) in elephant urine. ...
Figure 8: Example of a good accuracy test while analyzing hormone levels of pregnanediol glucuronide (Pdg) in elephant urine. ...
... and pregnanediol-3-glucuronide (the major metabolite of progesterone), measured in daily urine specimens. 6 7 Although no ...
... and pregnanediol-3-glucuronide (PDG). All participants ovulated in both cycles. ...
Buy generic darifenacin online canada» Cross comprising him pregnanediol backstretches, few veloplasty Home relents his simple- ...
50 μL of solubilized fecal samples were used for PdG and E1C EIA, using pregnanediol-3-glucuronide-BSA antibody and estrone-3- ... Fecal samples were then analyzed for estrone conjugates (E1C) and pregnanediol-3-glucuronide (PdG) using previously described ...
Microautoradiograms of rat skin applied with 3H-pregnanediol ointment suggested that the drug was absorbed through stratum ... Thirty minutes after intraperitoneal injection of 3H-pregnanediol in female mice, high concentration of the radioactivity was ... Absorption, distribution, and excretion of 3H-pregnanediol after its percutaneous or intraperitoneal administration in female ...
Alpha-Pregnanediol and Beta-Pregnanediol are metabolites of progesterone, and they are used as surrogate markers because they ... Alpha-Pregnanediol in mens urine is a significant metabolite of progesterone, and its levels can provide valuable insights ...
Peters, R., Yasar, S., Anderson, C. S., Andrews, S., Antikainen, R., Arima, H., Beckett, N., Beer, J. C., Bertens, A. S., Booth, A., van Boxtel, M., Brayne, C., Brodaty, H., Carlson, M. C., Chalmers, J., Corrada, M., DeKosky, S., Derby, C., Dixon, R. A., Forette, F., & 39 othersGanguli, M., van Gool, W. A., Guaita, A., Hever, A. M., Hogan, D. B., Jagger, C., Katz, M., Kawas, C., Kehoe, P. G., Keinanen-Kiukaanniemi, S., Kenny, R. A., Köhler, S., Kunutsor, S. K., Laukkanen, J., Maxwell, C., Peggy McFall, G., van Middelaar, T., Moll van Charante, E. P., Ng, T. P., Peters, J., Rawtaer, I., Richard, E., Rockwood, K., Rydén, L., Sachdev, P. S., Skoog, I., Skoog, J., Staessen, J. A., Stephan, B. C. M., Sebert, S., Thijs, L., Trompet, S., Tully, P. J., Tzourio, C., Vaccaro, R., Vaaramo, E., Walsh, E., Warwick, J. & Anstey, K. J., Jan 21 2020, In: Neurology. 94, 3, p. 1-15 15 p.. Research output: Contribution to journal › Article › peer-review ...
Markers first big success was in isolating pregnanediol from bulls urine. From this substance he synthesized progesterone. ...
Pregnanediol: a compound found in womens urine during certain phases of the menstrual cycle and in the urine of pregnant women ... Pregnanediol : پروجیسٹرون سے بولی اخراج پروڈکٹ , Hcg : حمل کا ہارمون , Brace : دانتوں کو برابر کرنے والی تاریں , Orthodontist ...
Core services, facilities, equipment and research support offered by the National Primate Research Centers
You cannot have both tests and return labels in the cart ...
Estrogen and progesterone metabolites (?-pregnanediol and ?-pregnanediol) for this profile are all tested (9x) by GC-MS/MS. ... Estrogen and progesterone metabolites (?-pregnanediol and ?-pregnanediol) for this profile are all tested (9x) by GC-MS/MS. ...
a-Pregnanediol. *Total progesterone. *This is measured across the entire menstrual cycle ...
Estrogen and progesterone metabolites (a-pregnanediol and b-pregnanediol) for this profile are all tested (9x) by GC-MS/MS. ... Estrogen and progesterone metabolites (a-pregnanediol and b-pregnanediol) for this profile are all tested (9x) by GC-MS/MS. ...
Pregnanediol / blood; Pregnanolone / blood; Premenstrual Dysphoric Disorder / metabolism; Progesterone / pharmacology; Young ...
Dive into the research topics of The effect of RU486 administered during the proliferative and secretory phase of the cycle on the bleeding pattern, hormonal parameters and the endometrium. Together they form a unique fingerprint. ...

No FAQ available that match "pregnanediol"

No images available that match "pregnanediol"